SGLT-2 Therapy Center

When the first SGLT-2 inhibitor came to the market we went to doctors all over the country and asked them their opinions on this new class of drugs. The overwhelming response was “wait and see.” We went back to them 3 months later and although some of them had tried …

There was a lot of great information at this year’s ADA Scientific Sessions on the sodium glucose co-transporter 2 (SGLT2) inhibitors both alone and in combination with other medications, and we have a review for you. Canagliflozin  Canagliflozin has demonstrated improvement in glycemic control, body weight, and blood pressure across …

Available studies to date looking at the benefits of using SGLT-2 inhibitors have shown positive results…. The discovery of sodium-glucose co-transporter 2 (SGLT2) inhibitors, with a novel mechanism independent of insulin secretion or sensitization, offered a new therapeutic approach for the management of type 2 diabetes mellitus. The aim of this …

Our publisher, Steve Freed, had a chance to talk with Dr. Stanley Schwartz, asking questions and getting some in-depth and very informative answers on exactly how SGLT-2 Inhibitors work.  Steve Freed: Regarding the SGLT2 drugs that are now available, I know that a lot of physicians just refuse to write …

In this Homerun Slides series, we review some issues around the Diabetic Management of the Obese Patient including; Potential Causes of Weight Gain with Treatment of Type 2 Diabetes; Weight Reduction Issues – Non-Insulin; and treatment with SGLT-2 Inhibitors with Incretins (GLP-1’s or DPP-IV’s)…. See more SGLT-2 Resources To download …

  In this special feature for our series on SGLT2 inhibitors, we are extremely pleased to present this comprehensive slide series from the WorldWIDE Initiative for Diabetes Education. In this subset of their series, the Role of the Kidneys is examined and the effects of SGLT2 inhibitors is explained….

Researchers track data on antidiabetic prescriptions dispensed from retail pharmacies in the US and note some interesting prescribing patterns. What is the most antidiabetic drug dispensed?… See more SGLT-2 Resources Despite the ability of nonpharmacological methods such as lifestyle interventions and bariatric surgery to improve type 2 diabetes outcomes, most …

John Anderson, MD, gives us a brief introduction to himself and talks about how, as an internal medicine specialist, he deals with a whole range of issues related to diabetes which he see in his patients. More videos with John Anderson, MD: Thoughts on SGLT-2 Inhibitors What is the ADA …

John Anderson, MD, talks about the efforts of the American Diabetes Association, and how they are using the successful experiences they have gained through landmark studies such as the Diabetes Prevention Program (DPP), applying this knowledge to new initiatives such as outreach into the community through the YMCA and other …

John Anderson, MD, talks about how clinicians should look at more than just a specific A1c number when beginning treatment for diabetes explaining that the measure is really only a way to project future risk. Factors such as family history, ethnic background and other characteristics may be more relevant. But …